Cargando…
Dimethyl fumarate–induced lymphopenia in MS due to differential T-cell subset apoptosis
OBJECTIVE: To examine the mechanism underlying the preferential CD8(+) vs CD4(+) T-cell lymphopenia induced by dimethyl fumarate (DMF) treatment of MS. METHODS: Total lymphocyte counts and comprehensive T-cell subset analyses were performed in high-quality samples obtained from patients with MS prio...
Autores principales: | Ghadiri, Mahtab, Rezk, Ayman, Li, Rui, Evans, Ashley, Luessi, Felix, Zipp, Frauke, Giacomini, Paul S., Antel, Jack, Bar-Or, Amit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365096/ https://www.ncbi.nlm.nih.gov/pubmed/28377940 http://dx.doi.org/10.1212/NXI.0000000000000340 |
Ejemplares similares
-
Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis
por: Ghadiri, Mahtab, et al.
Publicado: (2020) -
Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
Publicado: (2018) -
Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
por: Nakhaei-Nejad, Maryam, et al.
Publicado: (2017) -
A Case of Progressive Multifocal Leukoencephalopathy in a Fumaric
Acid-Treated Psoriasis Patient With Severe Lymphopenia Among Other Risk
Factors
por: Engel, Sinah, et al.
Publicado: (2021) -
Immunological Predictors of Dimethyl Fumarate‐Induced Lymphopenia
por: Diebold, Martin, et al.
Publicado: (2022)